Answers are grounded in this paper and cite their sources.
Clinical trials in neurodegenerative diseases often encounter selective enrollment and under-representation of certain patient populations. This delays drug development and substantially limits the generalizability of clinical trial results. To inform recruitment and retention strategies, and to better understand the generalizability of clinical trial populations, we investigated which factors drive participation.
No takes yet. Share an insight, caveat, or question.
Weemering et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: